華陽集團(002906.SZ):中山中科及中科白雲已合計減持1422萬股
格隆匯9月1日丨華陽集團(002906.SZ)公佈,公司於近日收到持股5%以上股東中山中科及中科白雲發來的《關於股份減持進展的吿知函》。截至2021年8月31日,中山中科、中科白雲此次減持計劃減持數量已過半、通過競價交易減持公司股份計劃時間已過半;2021年7月8日至2021年8月31日期間,中山中科及中科白雲減持公司股份比例超過1%。
其中,中山中科已於2021年5月28日-8月31日合計減持887萬股,佔公司2021年8月31日總股本比例1.87%;中科白雲已於2021年5月28日-8月31日合計減持535萬股,佔公司2021年8月31日總股本比例1.13%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.